Loading data for SER — first visit, this takes a few seconds.
Serina Therapeutics, Inc. (SER)
NYSE American: SER
· 即時價格 · USD
2.62
+0.12 (4.80%)
收盤價： Sep 04, 2026, 4:41 PM
股價、關鍵數字和最新消息，都在這一頁。
Serina Therapeutics, Inc.（SER）股價、分析與資料
無可用資料
| 買價 | 0 |
| 市值 | 66.7M |
| 營收 (ttm) | 0 |
| 淨利（ttm） | -23.9M |
| 0.00 | |
| -1.87 | |
| n/a | |
| -2.5 | |
| P/B (ttm) | 3.56 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 0 |
| 成交量 | 70,925 |
| 20 日平均成交量 | 78,739 |
| 開盤價 | 2.50 |
| 前收盤價 | 2.50 |
| 當日區間 | 2.42 - 2.65 |
| 52 週範圍 | 1.22 - 5.83 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early ...
完整的公司簡介財報驚奇
Serina Therapeutics 已於 Aug 13, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.52 低於預期 -0.17, 年增 21.21% 成長.
